<?xml version="1.0" encoding="UTF-8"?>
<ReportSnapshot Major="1" Minor="0" Revision="1">
	<CoIDs>
		<CoID Type="RepNo">A3167</CoID>
		<CoID Type="CompanyName">Oxford BioMedica plc</CoID>
	</CoIDs>
	<Issues>
		<Issue ID="1" Type="C" Desc="Common Stock" Order="1">
			<IssueID Type="Name">Ordinary shares</IssueID>
			<IssueID Type="Ticker">OXB</IssueID>
			<IssueID Type="CUSIP">G6836F106</IssueID>
			<IssueID Type="ISIN">GB0006648157</IssueID>
			<IssueID Type="RIC">OXB.L</IssueID>
			<IssueID Type="SEDOL">0664815</IssueID>
			<IssueID Type="DisplayRIC">OXB.L</IssueID>
			<IssueID Type="InstrumentPI">315548</IssueID>
			<IssueID Type="QuotePI">1079729</IssueID>
			<Exchange Code="LON" Country="GBR">London Stock Exchange (LON)</Exchange>
			<MostRecentSplit Date="2010-12-14">1.05479</MostRecentSplit>
		</Issue>
	</Issues>
	<CoGeneralInfo>
		<CoStatus Code="1">Active</CoStatus>
		<CoType Code="EQU">Equity Issue</CoType>
		<LastModified>2015-10-31</LastModified>
		<LatestAvailableAnnual>2014-12-31</LatestAvailableAnnual>
		<LatestAvailableInterim>2015-06-30</LatestAvailableInterim>
		<Employees LastUpdated="2015-06-30">192</Employees>
		<SharesOut Date="2015-12-31" TotalFloat="2161890572.0">2574252580.0</SharesOut>
		<ReportingCurrency Code="GBP">British Pounds</ReportingCurrency>
		<MostRecentExchange Date="2016-02-22">0.70681</MostRecentExchange>
	</CoGeneralInfo>
	<TextInfo>
		<Text Type="Business Summary" lastModified="2015-06-24T04:15:50">Oxford BioMedica plc is a United Kingdom-based gene and cell therapy research and development business. The Company is lentiviral vector and cell therapy research, development and manufacture. It provides a platform of technologies and capabilities with which it designs, develops and manufactures gene and cell-based medicines. The Company's clinical pipeline is targeting Parkinson's disease, selected cancers and a number of serious eye diseases. The Company has four clinical programs in active development and two other products, including EncorStat and OXB-102, being readied for Phase I/II. EncorStat is being studied for the prevention of corneal graft rejection. OXB-102 is being studied to target Parkinson's disease.</Text>
		<Text Type="Financial Summary" lastModified="2015-10-31T11:41:43">BRIEF: For the six months ended 30 June 2015, Oxford BioMedica plc revenues decreased 7% to L4.4M. Net loss increased 28% to L6.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development costs increase of 34% to L9.2M (expense), Administrativeexpenses increase of 38% to L2.5M (expense), Financecosts increase of 64% to L348K (expense).</Text>
	</TextInfo>
	<contactInfo lastUpdated="2016-01-05T21:58:01">
		<streetAddress line="1">Windrush Court,Transport Way</streetAddress>
		<streetAddress line="2"></streetAddress>
		<streetAddress line="3"></streetAddress>
		<city>OXFORD</city>
		<state-region></state-region>
		<postalCode>OX4 6LT</postalCode>
		<country code="GBR">United Kingdom</country>
		<contactName>Tim Watts</contactName>
		<contactTitle>Chief Financial Officer, Company Secretary, Executive Director</contactTitle>
		<phone>
			<phone type="mainphone">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>1865</city-areacode>
				<number>783000</number>
			</phone>
			<phone type="mainfax">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>1865</city-areacode>
				<number>783001</number>
			</phone>
			<phone type="contactphone">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>1865</city-areacode>
				<number>783000</number>
			</phone>
		</phone>
	</contactInfo>
	<webLinks lastUpdated="2013-08-01T22:46:06"><webSite mainCategory="Home Page">http://www.oxfordbiomedica.co.uk</webSite><eMail mainCategory="Company Contact/E-mail">investor-relations@oxfordbiomedica.co.uk</eMail></webLinks>
	<peerInfo lastUpdated="2016-01-05T21:58:01">
		<IndustryInfo>
			<Industry type="TRBC" order="1" reported="0" code="5620201011" mnem="">Bio Therapeutic Drugs</Industry>
			<Industry type="NAICS" order="1" reported="0" code="54171" mnem="">Research and Development in the Physical, Engineering, and Life Sciences</Industry>
			<Industry type="NAICS" order="2" reported="0" code="325412" mnem="">Pharmaceutical Preparation  Manufacturing</Industry>
			<Industry type="SIC" order="1" reported="0" code="8731" mnem="">Commercial Physical Research</Industry>
			<Industry type="SIC" order="2" reported="0" code="2834" mnem="">Pharmaceutical Preparations</Industry>
		</IndustryInfo>
	</peerInfo>
	<officers>
		<officer rank="1" since="08/28/2008">
			<firstName>John</firstName>
			<mI></mI>
			<lastName>Dawson</lastName>
			<age>55 </age>
			<title startYear="2008" startMonth="10" startDay="13" iD1="CEO" abbr1="CEO" iD2="EDR" abbr2="Exec. Dir.">Chief Executive Officer, Executive Director</title>
		</officer>
		<officer rank="2" since="02/09/2012">
			<firstName>Tim</firstName>
			<mI></mI>
			<lastName>Watts</lastName>
			<age>57 </age>
			<title startYear="2012" startMonth="02" startDay="09" iD1="CFO" abbr1="CFO" iD2="EDR" abbr2="Exec. Dir.">Chief Financial Officer, Company Secretary, Executive Director</title>
		</officer>
		<officer rank="3" since="09/01/2014">
			<firstName>Paul</firstName>
			<mI></mI>
			<lastName>Blake</lastName>
			<age>66 </age>
			<title startYear="2014" startMonth="09" startDay="01" iD1="EDR" abbr1="Exec. Dir." iD2="OTH" abbr2="Other">Executive Director, Chief Development Officer</title>
		</officer>
		<officer rank="4" since="05/2002">
			<firstName>Peter</firstName>
			<mI></mI>
			<lastName>Nolan</lastName>
			<age>62 </age>
			<title startYear="2014" startMonth="" startDay="" iD1="EDR" abbr1="Exec. Dir." iD2="OTH" abbr2="Other">Executive Director, Chief Business Officer</title>
		</officer>
	</officers>
	<Ratios PriceCurrency="GBP" ReportingCurrency="GBP" ExchangeRate="1.00000" LatestAvailableDate="2014-12-31">
		<Group ID="Price and Volume">
			<Ratio FieldName="NPRICE" Type="N">0.06550</Ratio>
			<Ratio FieldName="NHIG" Type="N">0.13375</Ratio>
			<Ratio FieldName="NLOW" Type="N">0.05390</Ratio>
			<Ratio FieldName="PDATE" Type="D">2016-02-23T00:00:00</Ratio>
			<Ratio FieldName="VOL10DAVG" Type="N">2.45283</Ratio>
			<Ratio FieldName="EV" Type="N">155.42500</Ratio>
		</Group>
		<Group ID="Income Statement">
			<Ratio FieldName="MKTCAP" Type="N">168.62000</Ratio>
			<Ratio FieldName="AREV" Type="N">13.61800</Ratio>
			<Ratio FieldName="AEBITD" Type="N">-9.51400</Ratio>
			<Ratio FieldName="ANIAC" Type="N">-8.66100</Ratio>
		</Group>
		<Group ID="Per share data">
			<Ratio FieldName="AEPSXCLXOR" Type="N">-0.00429</Ratio>
			<Ratio FieldName="AREVPS" Type="N">0.00674</Ratio>
			<Ratio FieldName="ABVPS" Type="N">0.00898</Ratio>
			<Ratio FieldName="ACSHPS" Type="N">0.00553</Ratio>
			<Ratio FieldName="ACFSHR" Type="N">-0.00374</Ratio>
			<Ratio FieldName="ADIVSHR" Type="N">0.00000</Ratio>
		</Group>
		<Group ID="Other Ratios">
			<Ratio FieldName="AGROSMGN" Type="N">67.57233</Ratio>
			<Ratio FieldName="AROEPCT" Type="N">-54.23803</Ratio>
			<Ratio FieldName="APR2REV" Type="N">12.38214</Ratio>
			<Ratio FieldName="APEEXCLXOR" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="APRICE2BK" Type="N">7.29486</Ratio>
			<Ratio FieldName="Employees" Type="N">192</Ratio>
		</Group>
	</Ratios>
	<ForecastData ConsensusType="Mean" CurFiscalYear="2015" CurFiscalYearEndMonth="12" CurInterimEndCalYear="2015" CurInterimEndMonth="9" EarningsBasis="PRX">
		<Ratio FieldName="ConsRecom" Type="N">
			<Value PeriodType="CURR">2</Value>
		</Ratio>
		<Ratio FieldName="TargetPrice" Type="N">
			<Value PeriodType="CURR">0.14500</Value>
		</Ratio>
		<Ratio FieldName="ProjLTGrowthRate" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjPE" Type="N">
			<Value PeriodType="CURR">-14.23913</Value>
		</Ratio>
		<Ratio FieldName="ProjSales" Type="N">
			<Value PeriodType="CURR">14.45700</Value>
		</Ratio>
		<Ratio FieldName="ProjSalesQ" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjEPS" Type="N">
			<Value PeriodType="CURR">-0.00460</Value>
		</Ratio>
		<Ratio FieldName="ProjEPSQ" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjProfit" Type="N">
			<Value PeriodType="CURR">-13.79300</Value>
		</Ratio>
		<Ratio FieldName="ProjDPS" Type="N">
			<Value PeriodType="CURR">0.00000</Value>
		</Ratio>
	</ForecastData>
</ReportSnapshot>
